haloperidol has been researched along with Torsade de Pointes in 39 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous haloperidol is the agent of choice for controlling severe agitated delirium in seriously ill cardiac patients in many institutions." | 8.79 | Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. ( Di Salvo, TG; O'Gara, PT, 1995) |
| "Since an antipsychotic drug haloperidol has been clinically reported to induce QT interval prolongation and torsade de pointes, in this study its risk stratification for the onset of torsade de pointes was performed by using the chronic atrioventricular block canine model with a Holter electrocardiogram." | 7.85 | Assessment of Safety Margin of an Antipsychotic Drug Haloperidol for Torsade de Pointes Using the Chronic Atrioventricular Block Dogs. ( Ando, K; Cao, X; Izumi-Nakaseko, H; Nakamura, Y; Sugiyama, A; Wada, T, 2017) |
| "Retrospective analysis of a previously reported case-control study of risk factors for haloperidol-induced torsade de pointes." | 7.74 | Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol. ( Cariera, BL; Kovacs, R; McCabe, GP; Mi, D; Rosman, H; Sharma, N; Tisdale, JE, 2007) |
| "To report a case of torsade de pointes related to the administration of high-dose intravenous haloperidol for the treatment of severe agitation." | 7.70 | Haloperidol-induced torsade de pointes. ( O'Brien, JM; Rockwood, RP; Suh, KI, 1999) |
| "In particular, torsade de pointes, a polymorphic ventricular tachyarrhythmia, has been associated with both intravenous and oral haloperidol administration." | 6.42 | Torsade de pointes associated with the administration of intravenous haloperidol:a review of the literature and practical guidelines for use. ( Balk, RA; Hassaballa, HA, 2003) |
| "Several cases of torsade de pointes have been reported in association with the use of oral haloperidol." | 6.40 | Torsade de pointes and low-dose oral haloperidol. ( Ditmanson, L; Jackson, T; Phibbs, B, 1997) |
| "Intravenous haloperidol is the agent of choice for controlling severe agitated delirium in seriously ill cardiac patients in many institutions." | 4.79 | Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. ( Di Salvo, TG; O'Gara, PT, 1995) |
| "Since an antipsychotic drug haloperidol has been clinically reported to induce QT interval prolongation and torsade de pointes, in this study its risk stratification for the onset of torsade de pointes was performed by using the chronic atrioventricular block canine model with a Holter electrocardiogram." | 3.85 | Assessment of Safety Margin of an Antipsychotic Drug Haloperidol for Torsade de Pointes Using the Chronic Atrioventricular Block Dogs. ( Ando, K; Cao, X; Izumi-Nakaseko, H; Nakamura, Y; Sugiyama, A; Wada, T, 2017) |
| "Many drugs, including haloperidol, are linked with a risk of QTc-prolongation, which can lead to Torsade de Pointes and sudden cardiac death." | 3.83 | Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium. ( Foulon, V; Spriet, I; Vandael, E; Vandenberghe, J; Vandenberk, B; Willems, R, 2016) |
| "Completion of a survey containing 10 hypothetical ICU cases in which patients had agitated delirium for which a psychiatrist recommended intravenous haloperidol 5 mg every 6 hours." | 3.79 | Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluation. ( Al-Qadheeb, NS; Devlin, JW; Estes, NA; Fongemie, JM; Roberts, RJ; Ruthazer, R; Temtanakitpaisan, Y, 2013) |
| "Retrospective analysis of a previously reported case-control study of risk factors for haloperidol-induced torsade de pointes." | 3.74 | Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol. ( Cariera, BL; Kovacs, R; McCabe, GP; Mi, D; Rosman, H; Sharma, N; Tisdale, JE, 2007) |
| "Medical records were reviewed retrospectively to identify consecutive patients who were admitted to our neuropsychiatry service with the presenting complaint of dementia (DSM-IV) with agitation and who were given intramuscular ziprasidone and then administered an electrocardiogram (ECG) (N = 23)." | 3.73 | A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. ( Brown, FW; Greco, KE; Tune, LE; Van Horn, WA, 2005) |
| "A 42-year-old woman who underwent single lung transplantation who received tacrolimus and a 58-year-old woman with pneumonia and multiple comorbidities who received haloperidol both experienced drug-induced prolongation of cardiac repolarization." | 3.72 | Prolonged cardiac repolarization after tacrolimus and haloperidol administration in the critically ill patient. ( Akers, WS; Davis, GA; Flynn, JD; Green, AE; Strobel, G; Winstead, PS, 2004) |
| "To report a case of torsade de pointes related to the administration of high-dose intravenous haloperidol for the treatment of severe agitation." | 3.70 | Haloperidol-induced torsade de pointes. ( O'Brien, JM; Rockwood, RP; Suh, KI, 1999) |
| " Administration of large intravenous doses of haloperidol was necessary for control of psychomotor agitation due to delirium." | 3.70 | Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. ( Bélisle, S; Carrier, M; Cartier, R; Denault, AY; Perrault, LP, 2000) |
| "In particular, torsade de pointes, a polymorphic ventricular tachyarrhythmia, has been associated with both intravenous and oral haloperidol administration." | 2.42 | Torsade de pointes associated with the administration of intravenous haloperidol:a review of the literature and practical guidelines for use. ( Balk, RA; Hassaballa, HA, 2003) |
| "Several cases of torsade de pointes have been reported in association with the use of oral haloperidol." | 2.40 | Torsade de pointes and low-dose oral haloperidol. ( Ditmanson, L; Jackson, T; Phibbs, B, 1997) |
| "We examined the incidence of arrhythmias, changes in heart rate, and prolongation of QT interval in isolated Langendorff-perfused rat and guinea pig hearts after they were exposed to nanomolar concentrations of haloperidol." | 1.35 | Apparent desensitization of the effects of sigma receptor ligand haloperidol in isolated rat and guinea pig hearts after chronic treatment. ( Fialova, K; Jarkovsky, J; Krizanova, O; Novakova, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (30.77) | 18.2507 |
| 2000's | 15 (38.46) | 29.6817 |
| 2010's | 11 (28.21) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Mirams, GR | 1 |
| Cui, Y | 1 |
| Sher, A | 1 |
| Fink, M | 1 |
| Cooper, J | 1 |
| Heath, BM | 1 |
| McMahon, NC | 1 |
| Gavaghan, DJ | 1 |
| Noble, D | 1 |
| Kramer, J | 1 |
| Obejero-Paz, CA | 1 |
| Myatt, G | 1 |
| Kuryshev, YA | 1 |
| Bruening-Wright, A | 1 |
| Verducci, JS | 1 |
| Brown, AM | 1 |
| Goto, A | 1 |
| Sakamoto, K | 1 |
| Kambayashi, R | 1 |
| Izumi-Nakaseko, H | 2 |
| Kawai, S | 1 |
| Takei, Y | 1 |
| Matsumoto, A | 1 |
| Kanda, Y | 1 |
| Sugiyama, A | 3 |
| Fongemie, JM | 1 |
| Al-Qadheeb, NS | 1 |
| Estes, NA | 1 |
| Roberts, RJ | 1 |
| Temtanakitpaisan, Y | 1 |
| Ruthazer, R | 1 |
| Devlin, JW | 1 |
| Howland, RH | 1 |
| Vandael, E | 1 |
| Vandenberk, B | 1 |
| Vandenberghe, J | 1 |
| Spriet, I | 1 |
| Willems, R | 1 |
| Foulon, V | 1 |
| Nakamura, Y | 1 |
| Cao, X | 1 |
| Wada, T | 1 |
| Ando, K | 1 |
| Dhein, S | 1 |
| Perlitz, F | 1 |
| Mohr, FW | 1 |
| Ginwalla, M | 1 |
| Biblo, LA | 1 |
| Paydak, H | 1 |
| Fialova, K | 1 |
| Krizanova, O | 1 |
| Jarkovsky, J | 1 |
| Novakova, M | 1 |
| Meyer-Massetti, C | 1 |
| Cheng, CM | 1 |
| Sharpe, BA | 1 |
| Meier, CR | 1 |
| Guglielmo, BJ | 1 |
| Mukherji, EH | 1 |
| Bauer, LK | 1 |
| Leskov, I | 1 |
| Januzzi, JL | 1 |
| Tanev, KS | 1 |
| Muzyk, AJ | 2 |
| Rayfield, A | 2 |
| Revollo, JY | 1 |
| Heinz, H | 2 |
| Gagliardi, JP | 2 |
| Rivelli, SK | 1 |
| Jiang, W | 1 |
| Cheung, D | 1 |
| Wolfe, B | 1 |
| Wald, H | 1 |
| Cumbler, E | 1 |
| Zareba, W | 1 |
| Lin, DA | 1 |
| Hassaballa, HA | 1 |
| Balk, RA | 1 |
| Akers, WS | 1 |
| Flynn, JD | 1 |
| Davis, GA | 1 |
| Green, AE | 1 |
| Winstead, PS | 1 |
| Strobel, G | 1 |
| Justo, D | 1 |
| Prokhorov, V | 1 |
| Heller, K | 1 |
| Zeltser, D | 1 |
| Vieweg, WV | 1 |
| Greco, KE | 1 |
| Tune, LE | 1 |
| Brown, FW | 1 |
| Van Horn, WA | 1 |
| Katchman, AN | 1 |
| Koerner, J | 1 |
| Tosaka, T | 1 |
| Woosley, RL | 1 |
| Ebert, SN | 1 |
| Tisdale, JE | 3 |
| Kovacs, R | 1 |
| Mi, D | 1 |
| McCabe, GP | 1 |
| Cariera, BL | 1 |
| Sharma, N | 1 |
| Rosman, H | 2 |
| Di Salvo, TG | 1 |
| O'Gara, PT | 1 |
| Stern, TA | 1 |
| Wilt, JL | 1 |
| Minnema, AM | 1 |
| Johnson, RF | 1 |
| Rosenblum, AM | 1 |
| Metzger, E | 1 |
| Friedman, R | 1 |
| Jackson, T | 1 |
| Ditmanson, L | 1 |
| Phibbs, B | 1 |
| Sharma, ND | 2 |
| Rosman, HS | 1 |
| Padhi, ID | 2 |
| Verdino, RJ | 1 |
| O'Brien, JM | 1 |
| Rockwood, RP | 1 |
| Suh, KI | 1 |
| Ryan, CJ | 1 |
| Pohjola-Sintonen, S | 1 |
| Metsäniitty, J | 1 |
| Perrault, LP | 1 |
| Denault, AY | 1 |
| Carrier, M | 1 |
| Cartier, R | 1 |
| Bélisle, S | 1 |
| Rasty, S | 1 |
| Su, KP | 1 |
| Chang, HC | 1 |
| Shen, WW | 1 |
| Henderson, RA | 1 |
| Lane, S | 1 |
| Henry, JA | 1 |
8 reviews available for haloperidol and Torsade de Pointes
| Article | Year |
|---|---|
The comparative cardiac effects of haloperidol and quetiapine: parsing a review.
Topics: Antipsychotic Agents; Dibenzothiazepines; Haloperidol; Heart; Humans; Quetiapine Fumarate; Risk Fact | 2014 |
The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Arrhythmias, Cardiac; Drug-Related Side Effects and A | 2010 |
[Effects of clinically available drugs on the repolarization process of the heart assessed by the in vivo canine models].
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Antitubercular Agents; Cat | 2003 |
Antipsychotic drugs and QT interval prolongation.
Topics: Age Factors; Algorithms; Antipsychotic Agents; Benzodiazepines; Death, Sudden, Cardiac; Dopamine Ant | 2003 |
Torsade de pointes associated with the administration of intravenous haloperidol:a review of the literature and practical guidelines for use.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Haloperidol; Humans; Injections, Intravenous | 2003 |
Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors.
Topics: Female; Haloperidol; Humans; Hypokalemia; Male; Mental Disorders; Prevalence; Psychotropic Drugs; Ri | 2005 |
Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients.
Topics: Aged; Delirium; Dose-Response Relationship, Drug; Electrocardiography; Female; Haloperidol; Heart Di | 1995 |
Torsade de pointes and low-dose oral haloperidol.
Topics: Administration, Oral; Aged; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; | 1997 |
31 other studies available for haloperidol and Torsade de Pointes
| Article | Year |
|---|---|
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; | 2011 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp T | 2013 |
Validation of Risk-Stratification Method for the Chronic Atrioventricular Block Cynomolgus Monkey Model and Its Mechanistic Interpretation Using 6 Drugs With Pharmacologically Distinct Profile.
Topics: Animals; Astemizole; Atrioventricular Block; DNA-Binding Proteins; Electrocardiography; Haloperidol; | 2022 |
Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluation.
Topics: Antipsychotic Agents; Critical Illness; Decision Making; Delirium; Haloperidol; Health Care Surveys; | 2013 |
Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Belgium; Electrocardiography; Follow-Up Studie | 2016 |
Assessment of Safety Margin of an Antipsychotic Drug Haloperidol for Torsade de Pointes Using the Chronic Atrioventricular Block Dogs.
Topics: Animals; Antipsychotic Agents; Atrioventricular Block; Chronic Disease; Dogs; Electrocardiography; F | 2017 |
An in vitro model for assessment of drug-induced torsade de pointes arrhythmia : effects of haloperidol and dofetilide on potential duration, repolarization inhomogeneities, and torsade de pointes arrhythmia.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relatio | 2008 |
Torsade de pointes following intravenous haloperidol administration in a patient with complete heart block.
Topics: Aged; Antipsychotic Agents; Cardiac Catheterization; Electrocardiography; Haloperidol; Heart Block; | 2009 |
Apparent desensitization of the effects of sigma receptor ligand haloperidol in isolated rat and guinea pig hearts after chronic treatment.
Topics: Animals; Arrhythmias, Cardiac; Electrocardiography; Guinea Pigs; Haloperidol; Heart; Heart Rate; Rat | 2009 |
Safety of antipsychotics in the setting of QTc prolongation: the utility of the JT index.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Bundle-Branch Block; Combined Modality T | 2011 |
Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Death, Sudden, Cardiac; Female; Haloperidol; Hosp | 2012 |
A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients.
Topics: Aged; Antipsychotic Agents; Cohort Studies; Death, Sudden, Cardiac; Electrocardiography; Female; Hal | 2012 |
Unsafe use of intravenous haloperidol: evaluation of recommendation-concordant care in hospitalized elderly adults.
Topics: Age Factors; Aged; Antipsychotic Agents; Colorado; Death, Sudden, Cardiac; Delirium; Electrocardiogr | 2013 |
Prolonged cardiac repolarization after tacrolimus and haloperidol administration in the critically ill patient.
Topics: Administration, Oral; Adult; Critical Illness; Dose-Response Relationship, Drug; Drug Administration | 2004 |
Excellent review of psychotropic drug-induced torsade de pointes.
Topics: Chronobiology Disorders; Haloperidol; Humans; Long QT Syndrome; Schizophrenia; Torsades de Pointes | 2005 |
A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Arrhythmias, Cardiac; Dementia; Electrocardiography; | 2005 |
Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cells, Cultured; Electrocardiography; ERG1 Potassium Channel; | 2006 |
Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol.
Topics: Adult; Aged; Antipsychotic Agents; Case-Control Studies; Electrocardiography; Female; Haloperidol; H | 2007 |
Continuous infusion of haloperidol in agitated, critically ill patients.
Topics: Critical Illness; Haloperidol; Humans; Infusions, Intravenous; Psychomotor Agitation; Torsades de Po | 1994 |
Torsade de pointes associated with the use of intravenous haloperidol.
Topics: Adult; Aged; Electrocardiography; Female; Haloperidol; Humans; Injections, Intravenous; Middle Aged; | 1993 |
Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill.
Topics: Adult; Alcoholism; Cardiomyopathy, Dilated; Delirium; Dose-Response Relationship, Drug; Electrocardi | 1993 |
Torsades de Pointes associated with intravenous haloperidol in critically ill patients.
Topics: Adult; Aged; Case-Control Studies; Critical Illness; Dopamine Antagonists; Electrocardiography; Fema | 1998 |
Torsade or not torsade? That is the question.
Topics: Antipsychotic Agents; Diagnosis, Differential; Electrocardiography; Haloperidol; Humans; Torsades de | 1998 |
Haloperidol-induced torsade de pointes.
Topics: Adult; Antipsychotic Agents; Electrocardiography; Female; Haloperidol; Humans; Long QT Syndrome; Tor | 1999 |
Haloperidol, midazolam and intravenous sedation.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Conscious Sedation; Dose-Response Relationship, Drug; Eme | 1999 |
Response to 'cardiotoxicity associated with use of intravenous haloperidol'.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Conscious Sedation; Emergency Services, | 1999 |
[Treatment of alcohol delirium can cause sudden cardiac death].
Topics: Adult; Alcohol Withdrawal Delirium; Antipsychotic Agents; Death, Sudden, Cardiac; Haloperidol; Human | 1997 |
Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery.
Topics: Anti-Dyskinesia Agents; Antipsychotic Agents; Coronary Artery Bypass; Critical Care; Delirium; Elect | 2000 |
The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.
Topics: Aged; Antipsychotic Agents; Critical Illness; Diagnosis, Computer-Assisted; Electrocardiography; Fem | 2001 |
Prolongation of QTc interval and antipsychotics.
Topics: Antipsychotic Agents; Death, Sudden, Cardiac; Haloperidol; Humans; Long QT Syndrome; Thioridazine; T | 2002 |
Life-threatening ventricular arrhythmia (torsades de pointes) after haloperidol overdose.
Topics: Drug Overdose; Electrocardiography; Female; Haloperidol; Humans; Middle Aged; Orphenadrine; Torsades | 1991 |